Citigroup maintains Bausch & Lomb at Buy, raises price target to $23 from $21
Citigroup reaffirmed its Buy rating for Bausch & Lomb and increased its price target to $23 from $21, suggesting a 12.7% upside from the last close. Recent analyst price targets for the company range from $19 to $24.
How this was made

The 30-second read
Why it matters
The upgrade may prompt short‑term buying but lacks fundamental catalyst.
Market read
Analyst target raise provides a modest trading signal for BHC.
What to watch
No new earnings data accompanies the upgrade; the move relies on analyst opinion alone.
Background
Citigroup's analyst note updates its valuation for Bausch & Lomb, a mid‑cap health‑care company.
Ticker impact
Citigroup raised its price target on Bausch & Lomb to $23 from $21, indicating a new bullish outlook.
likely upward pressure as investors price in the higher target
The price target increase suggests improved expectations, which can attract short‑term buyers.
Market effects
May lift sentiment in the ophthalmic and consumer health sector.
Limited to US markets where BHC trades.
Minimal global impact.
Counterpoint
The target raise could be premature if underlying earnings do not improve.
Key entities
- companyBausch & Lomb
Ophthalmic and consumer health products manufacturer.
- analystCitigroup
Investment bank providing the price target upgrade.


